Literature DB >> 22370470

Long-term effect of phacoemulsification on intraocular pressure using phakic fellow eye as control.

Ta C Chang1, Donald L Budenz, Anthony Liu, Won I Kim, Tam Dang, Chan Li, Andrew G Iwach, Sunita Radhakrishnan, Kuldev Singh.   

Abstract

PURPOSE: To investigate the long-term effect of phacoemulsification on intraocular pressure (IOP) in patients with ocular hypertension and open-angle glaucoma.
SETTING: Three multispecialty ophthalmology practices and one glaucoma specialty group.
DESIGN: Retrospective comparative case series.
METHODS: Review of medical records of patients with open-angle glaucoma or ocular hypertension who had had unilateral phacoemulsification (without other prior or concurrent ophthalmic procedure) with the fellow eye remaining phakic at least 3 years postoperatively.
RESULTS: Preoperatively, the IOP in the surgical and fellow eyes in the 29 patients was 15.66 mm Hg ± 3.33 (SD) and 15.64 ± 4.23 mm Hg (P=.98), respectively. Postoperatively, it was 13.56 ± 2.04 mm Hg and 14.92 ± 2.85 mm Hg, respectively, at 4.5 months (P=.06); 14.88 ± 3.20 mm Hg and 15.27 ± 3.19 mm Hg, respectively, at 1 year (P=.67); 14.16 ± 2.61 mm Hg and 14.95 ± 2.79 mm Hg, respectively, at 2 years (P=.37); and 14.68 ± 3.44 mm Hg and 14.68 ± 2.68 mm Hg at 3 years (P=1.00), respectively. There was no significant difference in the mean number of IOP-lowering medications used in the surgical eyes (1.96 ± 1.40) and fellow eyes (2.08 ± 1.44) postoperatively (P=.77).
CONCLUSIONS: In a cohort of ocular hypertensive and glaucoma patients, uncomplicated phacoemulsification had no significant IOP-lowering effect compared with the phakic fellow eye for up to 3 years postoperatively. There was also no difference between the mean number of postoperative IOP-lowering medications used in the surgical and fellow eyes. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned.
Copyright © 2012 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22370470     DOI: 10.1016/j.jcrs.2012.01.016

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  6 in total

1.  Two-year results of a multicenter study of the ab interno gelatin implant in medically uncontrolled primary open-angle glaucoma.

Authors:  Herbert Reitsamer; Chelvin Sng; Vanessa Vera; Markus Lenzhofer; Keith Barton; Ingeborg Stalmans
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-02-13       Impact factor: 3.117

2.  iStent with Phacoemulsification versus Phacoemulsification Alone for Patients with Glaucoma and Cataract: A Meta-Analysis.

Authors:  Monali S Malvankar-Mehta; Yiannis Iordanous; Yufeng Nancy Chen; Wan Wendy Wang; Sangita Shantilal Patel; John Costella; Cindy M L Hutnik
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

3.  Comparing iStent versus CyPass with or without phacoemulsification in patients with glaucoma: a meta-analysis.

Authors:  Ali Mahdavi Fard; Sangita P Patel; Leili Pourafkari; Nader D Nader
Journal:  Ther Adv Chronic Dis       Date:  2019-01-31       Impact factor: 5.091

4.  Commentary: Needle goniotomy in adults: Is it a viable minimally-invasive glaucoma surgery option?

Authors:  Vanita Pathak Ray
Journal:  Indian J Ophthalmol       Date:  2022-06       Impact factor: 2.969

5.  Feasibility, efficacy and safety of early lens extraction in patients with pseudoexfoliation glaucoma: a feasibility and pilot study.

Authors:  Sara Pose-Bazarra; María Jesús López-Valladares; Ignacio López-de-Ullibarri; Augusto Azuara-Blanco
Journal:  Eye (Lond)       Date:  2022-09-26       Impact factor: 4.456

6.  The effect of phacoemulsification surgery on intraocular pressure and anterior segment anatomy of the patients with cataract and ocular hypertension.

Authors:  Servet Cetinkaya; Zeynep Dadaci; Halil Ibrahim Yener; Nursen Oncel Acir; Yasemin Fatma Cetinkaya; Faik Saglam
Journal:  Indian J Ophthalmol       Date:  2015-09       Impact factor: 1.848

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.